OSI 211
Alternative Names: Liposomal lurtotecan; Lurtotecan liposomal; NX 211; OSI 211L; OSI-211Latest Information Update: 23 Sep 2021
At a glance
- Originator OSI Pharmaceuticals
- Class Alkaloids; Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hodgkin's disease; Ovarian cancer; Small cell lung cancer; Solid tumours